EVFM Bio play. Over 14% short-float. Testing the 50 EMA at an area of resistance. We need to break over $1.40 and this could really fly. Lot's of recent insider buying and Large stake by Morgan Stanley. EVO100 Phase 3, Fast track approval. Results expected 2022. Expecting $3+.